Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

84.66 -0.27 (-0.32%)
Official Closing Price Updated: 4:10 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch
Via Stocktwits
Topics Government
Investing $2,000 in Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth Nearly $135,000 Today
These stocks have all surged more than 1,000% since August 2020. 
Via The Motley Fool
Topics Artificial Intelligence
Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns
Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove investor interest. 
Via Benzinga
Topics Earnings
Why Merck Stock Slipped Today
A change in full-year guidance by management wasn't particularly welcome. 
Via The Motley Fool
Earnings Scheduled For July 29, 2025
 
Via Benzinga
Merck & Co's Earnings Outlook
 
Via Benzinga
P/E Ratio Insights for Merck & Co
 
Via Benzinga
Merck Commits To Veeva’s Vault CRM, Draws Wall Street Cheer: Retail’s Not Enthusiastic
Via Stocktwits
Is Merck & Co Gaining or Losing Market Support?
 
Via Benzinga
Why Merck (MRK) Shares Are Sliding Today
Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.2% in the afternoon session after the company reported second-quarter financial results that missed revenue expectations and revealed a... 
Via StockStory
Topics Artificial Intelligence Workforce
Merck CEO Sees Minimal EU Tariffs Impact, Warns Of Gardasil Challenges
Merck posted lower Q2 earnings as vaccine sales dropped, but oncology and animal health segments saw strong growth; 2025 guidance slightly raised. 
Via Benzinga
These S&P500 stocks are gapping in today's session
Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Tuesday and stay ahead of the market trends. 
Via Chartmill
AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday?
Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events. 
Via Benzinga
Merck’s Full Year Guidance Disappoints Investors But Retail Pins Hopes On $3B Cost-Cutting Plan
The $3 billion will be reinvested to support new product launches and its pipeline across multiple therapeutic areas, Merck said. 
Via Stocktwits
Topics World Trade
Which S&P500 stocks are moving before the opening bell on Tuesday?
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session. 
Via Chartmill
Merck Posts Q2 EPS Beat Revenue Slips
Via The Motley Fool
Merck’s (NYSE:MRK) Q2 Earnings Results: Revenue In Line With Expectations
Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% year on year to $15.81 billion. The company’s outlook for the full year was... 
Via StockStory
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results
From Merck & Co., Inc.
Via Business Wire
Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever
If you're looking for high-yield stocks in the healthcare sector, it's hard to beat this trio of industry giants offering yields of up to 3.9%. 
Via The Motley Fool
Topics Lawsuit
After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact
GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 billion. 
Via Benzinga
How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings
Merck offers a quarterly dividend amount of 81 cents per share. To receive $500 monthly, here's what you do. 
Via Benzinga
3 Surprisingly Underrated Stocks to Buy Right Now
These big pharma stocks arguably aren't receiving the respect they deserve. 
Via The Motley Fool
Topics Intellectual Property
What To Expect From Merck’s (MRK) Q2 Earnings
Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Tuesday before market open. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants. 
Via Benzinga
Topics Artificial Intelligence ETFs
How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma
AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles. 
Via Benzinga
Merck & Co. Inc. (NYSE:MRK): A Strong Value Investment with Undervalued Potential
Merck & Co. (MRK) is a top value stock with strong fundamentals—undervalued P/E, high profitability, stable finances, and steady growth, making it a smart pick for value investors. 
Via Chartmill
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst. 
Via Investor's Business Daily
Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock
The company had lined up a priority review in the hopes of winning an accelerated approval for its melanoma treatment. 
Via Investor's Business Daily
Merck Announces Fourth-Quarter 2025 Dividend
From Merck & Co., Inc.
Via Business Wire
MERCK & CO. INC. (NYSE:MRK) – A Quality Stock with Strong Fundamentals
MERCK & CO. INC. (NYSE:MRK) is a high-quality stock with strong profitability, efficient capital use, and a reliable dividend, making it a solid pick for long-term investors. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.